CLONIDINE HYDROCHLORIDE
Manufacturer: Lupin Pharmaceuticals, Inc.
Score: 141.0
Clonidine hydrochloride extended-release tablets are a centrally acting alpha 2-adrenergic agonist indicated for the treatment of attention deficit hyperactivity disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications. The drug is not a central nervous system stimulant and its mechanism of action in ADHD is not known. Clonidine hydrochloride extended-release tablets are available in 0.1 mg strength and should be swallowed whole, without crushing, chewing, or breaking. The dose should be initiated at 0.1 mg at bedtime and increased in increments of 0.1 mg/day at weekly intervals until the desired response is achieved, with a maximum dose of 0.4 mg/day.
Clonidine hydrochloride extended-release tablets are contraindicated in patients with a history of hypersensitivity reaction to clonidine.
Dose adjustments may be necessary when concomitantly administered with other medications, such as tricyclic antidepressants, antihypertensive drugs, and CNS depressants.
Initiate at 0.1 mg at bedtime, increase in increments of 0.1 mg/day at weekly intervals
Initiate at 0.1 mg at bedtime, increase in increments of 0.1 mg/day at weekly intervals